DRUG SUSCEPTIBILITY OF M. CHELONAE-ABSCESSUS COMPLEX
Abstract
We investigated 139 cultures of rapidly growing NTM of M. chelonae complex (90 – M. chelonae and 49 – M. abscessus) by broth microdilution method in Sensititre RAPMyco test. We established that M. abscessus were more often resistant to the main part of studied antimicrobial drugs that confirmed by statistical processing of data on the number of resistant strains of these species and analysis of Kaplan-Meier survival curves.
It should be emphasized that our data can coincide or differ from those given in other studies because there are significant features of NTM circulating between inanimate nature, animals and humans (spontaneous mutations, the incidence of diseases with certain types of treatment, etc.) in different regions of the world.
About the Authors
M. V. Makarova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
E. N. Khachturiants
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
M. A. Krasnova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом
Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
S. G. Safonova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
A. A. Khakhalina
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
V. I. Litvinov
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
References
1. Лабораторные исследования при туберкулезе / Под ред. В.И. Литвинова, А.М. Мороза. – М.: МНПЦБТ, 2013. – 342 с.
2. Литвинов В.И., Богородская Е.М., Борисов С.Е. Нетуберкулезные микобактерии, микобактериозы. – М.: МНПЦБТ, 2014. – 254 с.
3. Abuali M., Katariwala R., LaBombardi V. A comparison of the Sensititre® MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis // Eur. J. Clin. Microbiol. Infect. Dis. – 2011. – Vol. 31. – N. 5. – P. 835-839.
4. Akram S., Bhimji S. Mycobacterium Chelonae. – Treasure Island (FL): StatPearls Publishing, 2018. [Электронный доступ]. URL: https://www.ncbi.nlm.nih.gov/books/NBK430806/ (Дата обращения 12.04.2018).
5. Benwill J., Wallace R. Mycobacterium abscessus: challenges in diagnosis and treatment // Curr. Opin. Infect. Dis. – 2014. – Vol. 27. – N. 6. – P. 506-10.
6. Brown-Elliott B., Nash K., Wallace R. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria // Clin. Microbiol. Rev. – 2012. – Vol. 25. – N. 3. – P. 545-582.
7. Brown-Elliott B., Philley J. Rapidly growing Mycobacteria // Microbiol. Spectr. – 2017. – Vol. 5. – N. 1. doi: 10.1128/microbiolspec.TNMI7-0027-2016.
8. Cavusoglu C., Gurpinar T., Ecemis T. Evaluation of antimicrobial susceptibilities of rapidly growing mycobacteria by Sensititre RAPMYCO panel // New. Microbiol. – 2012. – Vol. 35. – N. 1. – P. 73-76.
9. Chazel M., Marchandin H., Keck N. et al. Evaluation of the SLOMYCO Sensititre® panel for testing the antimicrobial susceptibility of Mycobacterium marinum isolates // Ann. Clin. Microbiol. Antimicrob. – 2016. – Vol. 15. – P. 30.
10. Choi H., Kim S., Kim D. et al. Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease //Antimicrob. Agents. Chemother. – 2017. – Vol. 61. – N. 10. – pii: e01146-17.
11. Christianson S., Grierson W., Kein D. et al. Time-to-Detection of inducible macrolide resistance in Mycobacterium abscessus subspecies and its association with the erm (41) sequevar // PLoS One. – 2016. – Vol. 11. – Vol. 8. – e0158723.
12. CLSI. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard: 2nd Ed. CLSI document M24-A2. – Wayne, PA: Clinical and Laboratory Standards Institute, 2011. [Электронный ресурс]. URL: https://www.clsi.org/media/1463/m24a2_sample.pdf.
13. Cowman S., Burns K., Benson S. et al. The antimicrobial susceptibility of non-tuberculous mycobacteria // J. Infect. – 2016. – Vol. 72. – N. 3. – P. 324-31.
14. Griffith D., Aksamit T., Brown-Elliott B. et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases // J. Respir. Crit. Care Med. – 2007. – Vol. 175. – N. 4. – P. 367-416.
15. Griffith D. Nontuberculous mycobacterial lung disease // Curr. Opin. Infect. Dis. – 2010. – Vol. 23. – N. 2. – P. 185-90.
16. Griffith D. Mycobacterium abscessus subsp abscessus lung disease: ‘trouble ahead, trouble behind…’// F1000Prime. Rep. – 2014. – Nov 4; 6:107. doi: 10.12703/ P6-107.
17. Hall L., Jude K. P., Clark S.L. et al. Evaluation of the Sensititre MycoTB Plate for susceptibility testing of the Mycobacterium tuberculosis сomplex against first- and second-line agents //J. Clin. Microbiol. – 2012. – Vol. 50. – N. 11. – P. 3732-3734.
18. Han X., Dé I., Jacobson K. Rapidly growing mycobacteria: clinical and microbiologic studies of 115 cases // Am. J. Clin. Pathol. – 2007. – Vol. 128. – N. 4. – P. 612-21.
19. Hatakeyama S., Ohama Y., Okazaki M. et al. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan // BMC Infect. Dis. – 2017. – Vol. 17. – N. 1. – P. 197. doi: 10.1186/s12879-017-2298-8.
20. Heifets L. Drug susceptibility in the chemotherapy of mycobacterial infections. – CRC Press. Boca Raton Ann Arbor Boston. London. – 2000. – 212 p.
21. Heifets L. Mycobacterial infections caused by nontuberculous mycobacteria // Semin. Respir. Crit. Care Med. – 2004. – Vol. 25. – N. 3. – P. 283-295.
22. Huang Y., Liu M., Shen G. et al. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing // J. Microbiol. Immunol. Infect. – 2010. – Vol. 43. – N. 5. – P. 401-406.
23. Kasperbauer S., de Groote M. The treatment of rapidly growing mycobacterial infections // Clin. Chest. Med. – 2015. – Vol. 36. – N. 1. – P. 67-78.
24. Kim H., Lee S., Kim B., Kook Y. Allele-specific duplex polymerase chain reaction to differentiate Mycobacterium abscessus subspecies and to detect highly clarithromycin-resistant isolates // Indian. J. Med. Microbiol. – 2016. – Vol. 34. – N. 3. – P. 369-374.
25. Koh W., Stout J., Yew W. Advances in the management of pulmonary disease due to Mycobacterium abscessus complex// Int. J. Tuberc. Lung. Dis. – 2014. – Vol. 18. – N. 10. – P. 1141-1148.
26. Lee S., Yoo H., Kim S. et al. The drug resistance profile of Mycobacterium abscessus group strains from Korea // Ann. Lab. Med. – 2014. – Vol. 34. – N. 1. – P. 31-37.
27. Li Y., Tong X., Xu H. et al. Prevalence and Antimicrobial Susceptibility of Mycobacterium abscessus in a General Hospital, China // Biomed. Environ. Sci. – 2016. – Vol. 29. – N. 2. – P. 85-90. DOI: 10.3967/bes2016.009.
28. McShane P., Glassroth J. Pulmonary Disease Due to Nontuberculous Mycobacteria: Current State and New Insights // Chest. – 2015. – Vol. 148. – N. 6. –1517-1527.
29. Maurer F., Bruderer V., Ritter C. et al. Lack of antimicrobial bactericidal activity in Mycobacterium abscessus //Antimicrob. Agents. Chemother. – 2014. – Vol. 58. – N. 7. – P. 3828-3836.
30. Nagano H., Kinjo T., Nei Y. et al. Causative species of nontuberculous mycobacterial lung disease and comparative investigation on clinical features of Mycobacterium abscessus complex disease: A retrospective analysis for two major hospitals in a subtropical region of Japan // PLoS One. – 2017. – Vol. 12. – N. 10. – e0186826.
31. Nie W., Duan H., Huang H. et. al. Species identification and clarithromycin susceptibility testing of 278 clinical nontuberculosis mycobacteria isolates // Biomed. Res. Int. – 2015. – P. 506-598. DOI 10.1155/2015/506598. [Электронный документ]. URL: https://doaj.org/article/f93e475b0fcb4d7ab9d22bd87dab233d. (Дата обращения 12.04.2018).
32. Pang H., Li G., Wan L. et al. In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents // Int. J. Clin. Exp. Med. – 2015(а). – Vol. 8. – N. 9. – P. 15423-15431.
33. Pang H., Li G., Zhao X. et al. Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China // Biomed. Res. Int. – 2015(b). – DOI 10.1155/2015/419392. [Электронный документ]. URL: https://doaj.org/article/7f1acb2433bf4ea09ca68278c234a09b. (Дата обращения 12.04.2018).
34. Richter E., Andres S., Hillemann D. Current microbiological methods in the investigation of mycobacteria // Pneumologie. – 2015. – Vol. 69. – N. 5. – P. 276-281.
35. Set R., Rokade S., Agrawal S., Shastri J. Antimicrobial susceptibility testing of rapidly growing mycobacteria by microdilution – experience of a tertiary care centre // Indian. J. Med. Microbiol. – 2010. – Vol. 28. – N. 1. – P. 48-50.
36. Stout J., Koh W., Yew W. Update on pulmonary disease due to non-tuberculous mycobacteria // Int. J. Infect. Dis. – 2016. – Vol. 45. – P. 123-134.
37. Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections // Clin. Microbiol. Infect. – 2009. – Vol. 15. – N. 10. – P. 906-910.
38. Tortoli E., Kohl T., Brown-Elliott B. et al. Mycobacterium abscessus, a taxonomic puzzle // Int. J. Syst. Evol. Microbiol. – 2017. – Vol. 8. – N. 11. – P. 18070-18081.
39. van Ingen J., Boeree M., van Soolingen D. et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria // Drug Resist. Updat. – 2012. – Vol. 15. – N. 3. – P. 149-161.
40. van Ingen J., Kuijper E. Drug susceptibility testing of nontuberculous mycobacteria // Future Microbiol. – 2014. – Vol. 9. – N. 9. – P. 1095-1110.
41. van Ingen J. Microbiological diagnosis of nontuberculous mycobacterial pulmonary disease // Clin. Chest. Med. – 2015(a). – Vol. 36. – N. 1. – P. 43-54.
42. van Ingen J. Treatment of pulmonary disease caused by non-tuberculous mycobacteria // Lancet. Respir. Med. – 2015(b). – Vol. 3. – N. 3. – P. 179-180.
43. Wallace R. Diagnostic and therapeutic consideration in patients with pulmonary disease due to the rapidly growing mycobacteria // Semin. Respir. Infect. – 1986. – Vol. 1. – N. 4. – P. 230-233.
44. Woods G. Susceptibility testing for mycobacteria // Clin. Infect. Dis. – 2000(a). – Vol. 31. – N. 5. – P. 1209-1215.
45. Woods G., Bergmann J., Witebsky F. et al. Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum // J. Clin. Microbiol. – 2000(b). – Vol. 38. – P. 656-661.
46. Yamane N., Onaga S., Saitoh H. et al. Multicenter evaluation of a newly developed microdilution test, broth MIC NTM to determine minimum inhibitory concentrations of antimicrobial agents for nontuberculous mycobacteria // Rinsho. Byori. – 2002. – Vol. 50. – N. 4. – P. 381-391.
47. Yang S., Hsueh P., Lai H. et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan // Antimicrob. Agents. Chemother. – 2003. – Vol. 47. – N. 6. – P. 1958-1962.
48. Yano Y., Kitada S., Mori M. et al. Pulmonary disease caused by rapidly growing mycobacteria: a retrospective study of 44 cases in Japan // Respiration. – 2013. – Vol. 85. – N. 4. – P. 305-311.
49. Zelazny A., Root J. Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii // J. Clin. Microbiol. – 2009. – Vol. 47. – N. 7. – P. 1985-1995.
Review
For citations:
Makarova M.V., Khachturiants E.N., Krasnova M.A., Safonova S.G., Khakhalina A.A., Litvinov V.I. DRUG SUSCEPTIBILITY OF M. CHELONAE-ABSCESSUS COMPLEX. Tuberculosis and socially significant diseases. 2018;(2):22-30. (In Russ.)
Views:
25
Email this article 